Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.37 |
| ▸ | P2RY10 | O00398 | 8/20 | 0.36 |
| ▸ | GPR174 | Q9BXC1 | 8/20 | 0.36 |
| ▸ | GPR34 | Q9UPC5 | 5/20 | 0.36 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Threonine SCHEMBL6239870 | 0.97 | NOS3 (0.36) | NOS3NOS1NOS2SLC7A5P2RY10 | |
| Alanine SCHEMBL5168125 | 0.86 | SLC7A5 (0.42) | NOS3NOS1NOS2SLC7A5P2RY10 | |
| SCHEMBL3502798 | 0.86 | SLC1A5 (0.43) | NOS3NOS1NOS2SLC7A5P2RY10 | |
| SCHEMBL352049 | 0.86 | SLC1A5 (0.43) | NOS3NOS1NOS2SLC7A5P2RY10 | |
| Threonine SCHEMBL15324163 | 0.84 | P2RY10 (0.40) | NOS3NOS1NOS2SLC7A5P2RY10 | |
| Threonine SCHEMBL15323039 | 0.84 | P2RY10 (0.40) | NOS3NOS1NOS2SLC7A5P2RY10 | |
| Glycine SCHEMBL8588130 | 0.82 | GLRA1 (0.42) | NOS3NOS1NOS2SLC7A5P2RY10 | |
| SCHEMBL4752999 | 0.80 | SLC1A5 (0.40) | NOS3NOS1NOS2SLC7A5P2RY10 | |
| SCHEMBL12500454 | 0.80 | SLC1A5 (0.40) | NOS3NOS1NOS2SLC7A5P2RY10 | |
| SCHEMBL103942 | 0.80 | SLC7A5 (0.43) | NOS3NOS1NOS2SLC7A5P2RY10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024064810-A2 | SYSTEMS AND METHODS FOR IDENTIFYING AND TARGETING COLLATERAL LETHAL GENES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-03-28 | — | — | WO | disclosed |
| EP-1874933-B1 | PRODUCTION OF RECOMBINANT PROTEINS BY AUTOPROTEOLYTIC CLEAVAGE OF A FUSION PROTEIN | SANDOZ AG (CH) | 2014-11-19 | — | — | EP | disclosed |
| US-8372959-B2 | Production of recombinant proteins by autoproteolytic cleavage of a fusion protein | SANDOZ AG (CH) | 2013-02-12 | — | — | US | disclosed |
| US-20120107869-A1 | ORGANIC COMPOUNDS | BOEHRINGER INGELHEIM RCV GMBH & CO KG (AT) | 2012-05-03 | — | — | US | disclosed |
| US-8163890-B2 | Production of recombinant proteins by autoproteolytic cleavage of a fusion protein | SANDOZ AG (CH) | 2012-04-24 | — | — | US | disclosed |
| EP-2348053-A2 | Oligopeptide ligands | Sandoz AG (CH) | 2011-07-27 | — | — | EP | disclosed |
| US-20090203069-A1 | Organic compounds | BOEHRINGER INGELHEIM AUSTRIA GMBH (AT) | 2009-08-13 | — | — | US | disclosed |
| WO-2008092134-A2 | TUMOR-SPECIFIC ANTIGENS, CYTOTOXIC T LYMPHOCYTES RESPONSIVE THERETO, AND METHODS OF USING THE SAME | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2008-07-31 | — | — | WO | disclosed |
| EP-1874933-A2 | PRODUCTION OF RECOMBINANT PROTEINS BY AUTOPROTEOLYTIC CLEAVAGE OF A FUSION PROTEIN | Sandoz AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006113959-A2 | PRODUCTION OF RECOMBINANT PROTEINS BY AUTOPROTEOLYTIC CLEAVAGE OF A FUSION PROTEIN | SANDOZ AG (CH) | 2006-11-02 | — | — | WO | disclosed |
| US-6852838-B2 | Tyrosine kinase receptors and ligands | REGENERON PHARMACEUTICALS, INC. (US) | 2005-02-08 | — | — | US | disclosed |
| EP-0866860-B1 | NOVEL TYROSINE KINASE RECEPTORS AND LIGANDS | REGENERON PHARMA (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20020164702-A1 | Novel tyrosine kinase receptors and ligands | REGENERON PHARMACEUTICALS, INC. | 2002-11-07 | — | — | US | disclosed |
| US-6413740-B1 | NUCLEIC ACID WHICH CODES FOR MUSCLE SPECIFIC KINASE C-TERMINAL FRAGMENT OF HUMAN AGRIN; DIAGNOSIS AND TREATMENT OF MUSCLE DISORDERS AND NEUROMUSCLAR DISORDERS | REGENERON PHARMACEUTICALS, INC. | 2002-07-02 | — | — | US | disclosed |
| EP-0866860-A2 | NOVEL TYROSINE KINASE RECEPTORS AND LIGANDS | REGENERON PHARMACEUTICALS, INC. (US) | 1998-09-30 | — | — | EP | disclosed |
| US-5814478-A | ISOLATED NUCLEOTIDE SEQUENCE ENCODING A POLYPEPTIDE FOR TREATING MUSCULAR DISORDERS OR NERVOUS SYSTEM DISORDERS | REGENERON PHARMACEUTICALS, INC. (US) | 1998-09-29 | — | — | US | disclosed |
| US-5656473-A | GENETIC ENGINEERING | REGENERON PHARMACEUTICALS, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| WO-1997021811-A2 | NOVEL TYROSINE KINASE RECEPTORS AND LIGANDS | REGENERON PHARMACEUTICALS, INC. (US) | 1997-06-19 | — | — | WO | disclosed |
| EP-0767835-A1 | DENERVATED MUSCLE KINASE (DMK), A RECEPTOR OF THE TYROSINE KINASE SUPER FAMILY | REGENERON PHARMACEUTICALS, INC. (US) | 1997-04-16 | — | — | EP | disclosed |
| WO-1996002643-A1 | DENERVATED MUSCLE KINASE (DMK), A RECEPTOR OF THE TYROSINE KINASE SUPER FAMILY | REGENERON PHARMACEUTICALS, INC. (US) | 1996-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203069-A1 | Organic compounds | DNPEP, MRPL21, NPEPPS | NOS3 1109/4885NOS1 1024/4885NOS2 1063/4885 |
| US-20120107869-A1 | ORGANIC COMPOUNDS | DNPEP, MRPL21, NPEPPS | NOS3 1109/4885NOS1 1024/4885NOS2 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.